Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Finished Goods (2020 - 2026)

Cytek Biosciences filings provide 6 years of Finished Goods readings, the most recent being $11.5 million for Q4 2025.

  • On a quarterly basis, Finished Goods fell 22.78% to $11.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.5 million, a 22.78% decrease, with the full-year FY2025 number at $11.5 million, down 22.78% from a year prior.
  • Finished Goods hit $11.5 million in Q4 2025 for Cytek Biosciences, down from $20.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $22.8 million in Q1 2023 to a low of $9.1 million in Q2 2021.
  • Median Finished Goods over the past 5 years was $15.2 million (2025), compared with a mean of $15.4 million.
  • Biggest five-year swings in Finished Goods: soared 86.31% in 2022 and later plummeted 34.36% in 2024.
  • Cytek Biosciences' Finished Goods stood at $12.6 million in 2021, then increased by 29.48% to $16.3 million in 2022, then dropped by 9.96% to $14.7 million in 2023, then increased by 0.88% to $14.8 million in 2024, then decreased by 22.78% to $11.5 million in 2025.
  • The last three reported values for Finished Goods were $11.5 million (Q4 2025), $20.3 million (Q3 2025), and $16.9 million (Q2 2025) per Business Quant data.